| Luo, Ailin |
NCT04908553: Study on the Safety and Effectiveness of Remimazolam Tosilate for Injection for Short-term Elective Surgery in Adults |
|
|
| Completed | 4 | 650 | RoW | Remimazolam Tosilate for Injection 0.1mg/kg, low dose group, Remimazolam Tosilate for Injection 0.15mg/kg, medium dose group, Remimazolam Tosilate for Injection 0.2mg/kg, high dose group | Tongji Hospital | Hypotension During Surgery | 12/22 | 01/23 | | |
NCT06674226: Effects of Ciprofol on Postoperative Delirium and Outcomes in Elderly Patients Undergoing Major Thoracic Surgery |
|
|
| Recruiting | 4 | 214 | RoW | Ciprofol, Propofol | Wang Tianlong, Xiangya Hospital of Central South University, The Third Xiangya Hospital of Central South University, The First Hospital of Hebei Medical University, The First Affiliated Hospital of Nanchang University, Tongji Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Postoperative Delirium (POD) | 06/26 | 06/26 | | |
NCT04829409: The Effects of Three Different Ultrasound-guided Nerve Blocks in VATS |
|
|
| Recruiting | N/A | 90 | RoW | Paravertebral block, ESP block, MTP block | Huazhong University of Science and Technology | Thoracic Anesthesia, Nerve Block, Pain, Acute | 10/22 | 12/22 | | |
| Completed | N/A | 336 | RoW | Esketamine, Es group, Normal saline, Ns group | Ailin Luo, Maternal and Child Health Hospital of Hubei Province, Jingmen No.1 People's Hospital | Esketamine, Postpartum Depression | 03/24 | 03/24 | | |
NCT05810363: The Safety of Etomidate - Propofol Mixture vs Propofol in Total Intravenous Anesthesia During Abdominal Surgery |
|
|
| Recruiting | N/A | 468 | RoW | Etomidate - propofol mixture, EP, Propofol, P | Ailin Luo | Etomidate, Hypotension | 05/24 | 08/24 | | |
NCT06009991: The Dose Range of Remimazolam Besylate in Different Age Groups |
|
|
| Recruiting | N/A | 1876 | RoW | Remimazolam besylate, Propofol | Tongji Hospital, Renmin Hospital of Wuhan University, Wuhan University, The General Hospital of Central Theater Command, Taihe Hospital, Yichang Central People's Hospital, Jingzhou Central Hospital, Beijing Shijitan Hospital, Capital Medical University, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, First Affiliated Hospital of Fujian Medical University, Tianjin Nankai Hospital, Sichuan Provincial People's Hospital, Shanxi Bethune Hospital | Remimazolam, Anesthesia | 09/25 | 12/25 | | |
| luo, xiaoping |
| Recruiting | 4 | 80 | RoW | Leuprorelin Acetate Depot 3M, Leuprolide acetate Depot 3M | Takeda, Takeda | Central Precocious Puberty | 05/25 | 05/25 | | |
NCT05353192: A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Achondroplasia |
|
|
| Recruiting | 4 | 38 | RoW | Recombinant human growth hormone | GeneScience Pharmaceuticals Co., Ltd., Children's Hospital of Fudan University, Tongji Hospital, Children's Hospital of Nanjing Medical University, Jiangxi Province Children's Hospital, Chengdu Women's and Children's Central Hospital, Shandong Provincial Hospital, Shengjing Hospital, Shanghai Children's Hospital, Children's Hospital of The Capital Institute of Pediatrics, West China Second University Hospital, Sichuan University | Achondroplasia | 02/25 | 02/25 | | |
NCT05144035: A Real World Study of the Effect of Early PEG-rhGH Therapy on Cognitive Development of SGA Infants |
|
|
| Recruiting | 4 | 138 | RoW | PEG-rhGH, jintrolong | Tongji Hospital, GeneScience Pharmaceuticals Co., Ltd. | Small for Gestational Age Infant, Growth Hormone Treatment, Cognitive Developmental Disorder | 12/25 | 06/26 | | |
NCT04633057: A Study to Evaluating the Efficacy and Safety of Recombinant Long-acting Human Growth Hormone (TJ101) in Children With Growth Hormone Deficiency |
|
|
| Completed | 3 | 168 | RoW | TJ101, NordiFlex | TJ Biopharma Co., Ltd. | Pediatric Growth Hormone Deficiency | 07/23 | 07/23 | | |
| Completed | 3 | 20 | RoW | Velaglucerase Alfa, VPRIV | Takeda, Takeda | Gaucher Disease | 08/24 | 08/24 | | |
NCT05493709: Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects with Central Precocious Puberty |
|
|
| Recruiting | 3 | 93 | US, RoW | Leuprolide Mesylate, Subcutaneous injection of 42 mg Leuprolide | Foresee Pharmaceuticals Co., Ltd., QPS Holdings LLC, Changchun GeneScience Pharmaceutical Co., Ltd. | Puberty; Precocious, Central | 11/25 | 06/26 | | |
NCT04513171: Safety and Efficacy of Y-shape Pegylated Somatropin in Growth Hormone Deficiency Children |
|
|
| Completed | 2/3 | 434 | RoW | Y-shape pegylated somatropin, Norditropin®, Norditropin | Xiamen Amoytop Biotech Co., Ltd., Tongji Hospital | Growth Hormone Deficiency | 06/23 | 07/23 | | |
NCT03255694: A Study Extension Period of PEG-somatropin (Pegylated-somatropin) in the Treatment of Children With Idiopathic Short Stature |
|
|
| Active, not recruiting | 2 | 360 | RoW | PEG-somatropin, Polyethylene Glycol Recombinant Human Somatropin Injection | GeneScience Pharmaceuticals Co., Ltd., Tongji Hospital, The First Hospital of Jilin University, Affiliated Hospital of Jiangnan University, The First Affiliated Hospital with Nanjing Medical University, Shanghai Children's Hospital, The Children's Hospital of Zhejiang University School of Medicine, Children's Hospital of Fudan University | Dwarfism | 06/30 | 06/30 | | |
| Completed | N/A | 743 | RoW | | Changchun GeneScience Pharmaceutical Co., Ltd., Tongji Hospital | Turner Syndrome | 06/23 | 06/23 | | |
| Recruiting | N/A | 15 | RoW | Nitisinone, Orfadin® | Swedish Orphan Biovitrum | Hereditary Tyrosinemia, Type I | 06/27 | 06/27 | | |
NCT05137301: Performance of the Diagnostic Value of Bone Age Assessment Software Based on Deep Learning in Chinese Children |
|
|
| Recruiting | N/A | 1000 | RoW | X-ray bone age instrument | Tongji Hospital, GeneScience Pharmaceuticals Co., Ltd. | Endocrine Diseases | 12/24 | 12/24 | | |
NCT06110910: Long-term Efficacy and Safety Evaluation of Growth Hormone in Children in China(CGLS) |
|
|
| Recruiting | N/A | 10000 | RoW | Polvethylene glycol recombinant human growth hormone injection (PEG-rhGH) or recombinanthuman growth hormone injection (rhGH), PEG-rhGH or rhGH | Xiaoping Luo | Childhood Short Stature | 12/27 | 12/27 | | |
| Huang, Xiaolin |
NCT04263883: RCT of Addition of 3D Posture Corrective Orthosis to A Multimodal Program of Treatment Of Chronic Postural Neck Pain. |
|
|
| Recruiting | N/A | 50 | RoW | Study or Experimental Group | Huang Xiaolin | Neck Pain | 11/20 | 11/20 | | |
| ZHAO, Jianping |
CCGLC-001, NCT05713994: Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 300 | RoW | HAIC, hepatic arterial infusion chemotherapy of FOLFOX, Bevacizumab plus Atezolizumab, Avastin plus Tecentriq, Bevacizumab Biosimilar IBI305 plus sintilimab, Byvasda (B) plus S, Lenvatinib, Lenvima, Sorafenib, Nexavar, Donafenib, Zepsun, Regorafenib, stivarga, apatinib plus camrelizumab, Apa plus C, Anti-PD-1 monoclonal antibody, PD-1 inhibitor | Wan-Guang Zhang, Chinese Cooperative Group of Liver Cancer (CCGLC), Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province, Haplox Biotechnology Co., Ltd., Geneplus-Beijing Co. Ltd., The Second Affiliated Hospital of Fujian Medical University | Hepatocellular Carcinoma Non-resectable | 04/24 | 12/24 | | |
NCT04462185: A Prospective Cohort Study of Chinese Patients With Pulmonary Nodules: Prediction of Lung Cancer Using Noninvasive Biomarkers |
|
|
| Recruiting | N/A | 3000 | RoW | A genomic and transcriptomic landscape analysis | AnchorDx Medical Co., Ltd., The First Affiliated Hospital of Guangzhou Medical University, Tongji Hospital, Qilu Hospital of Shandong University, Shanghai Zhongshan Hospital, West China Hospital, Beijing Chao Yang Hospital, Johnson & Johnson (China) Investment Ltd. | Pulmonary Nodules | 06/24 | 12/24 | | |
NCT03651986: Diagnostic and Monitoring Significance of ctDNA Methylation Analysis by NGS in Benign and Malignant Pulmonary Nodules |
|
|
| Active, not recruiting | N/A | 10560 | RoW | ctDNA methylation analysis by NGS | AnchorDx Medical Co., Ltd., Xiangya Hospital of Central South University, West China Hospital, Shanghai Zhongshan Hospital, Shanghai Pulmonary Hospital affiliated to Tongji University, First Hospital of China Medical University, Guizhou Provincial People's Hospital, Shanghai Chest Hospital, First Affiliated Hospital, Sun Yat-Sen University, First Affiliated Hospital Xi'an Jiaotong University, Qilu Hospital of Shandong University, Inner Mongolia People's Hospital, The First Affiliated Hospital with Nanjing Medical University, The First Affiliated Hospital of Zhengzhou University, Second Hospital of Jilin University, LanZhou University, Peking University Third Hospital, The First People's Hospital of Yunnan, Shantou Affiliated Hospital of Sun Yat-Sen University, Ruijin Hospital, The Shanghai Jiao Tong University Medical School, Tongji Hospital, The First Affiliated Hospital of Guangzhou Medical University, Xijing Hospital, Air Force Medical University of PLA, Shenzhen People's Hospital, Henan Provincial People's Hospital, Beijing Chao Yang Hospital, Xiamen Second Hospital, The First Affiliated Hospital of Nanchang University | Pulmonary Nodules | 09/24 | 06/25 | | |
| Luo, Xin |
NCT06717152: Efficacy and Safety of SJP-0132 Eye Drops in Chinese Patients With Dry Eye Disease |
|
|
| Recruiting | 3 | 400 | RoW | SJP-0132, Placebo | Senju Pharmaceutical Science & Technology (Beijing) Co., Ltd., Senju Pharmaceutical Co., Ltd. | Dry Eye | 07/25 | 08/25 | | |
NCT04694781: Study of LVGN6051 (CD137 Agonist Antibody) in Advanced or Metastatic Malignancy |
|
|
| Completed | 1 | 18 | RoW | LVGN6051, Pembrolizumab | Lyvgen Biopharma Holdings Limited | Cancer | 10/23 | 10/23 | | |
NCT05486637: Vocal Emotion Communication With Cochlear Implants |
|
|
| Recruiting | 1 | 255 | US | Perception of acoustic cues to emotion, Production of acoustic cues to emotion | Father Flanagan's Boys' Home, Arizona State University, House Institute Foundation, University of Nebraska, National Institute on Deafness and Other Communication Disorders (NIDCD), Office of Behavioral and Social Sciences Research (OBSSR) | Cochlear Hearing Loss | 06/27 | 06/27 | | |
CCGLC-001, NCT05713994: Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 300 | RoW | HAIC, hepatic arterial infusion chemotherapy of FOLFOX, Bevacizumab plus Atezolizumab, Avastin plus Tecentriq, Bevacizumab Biosimilar IBI305 plus sintilimab, Byvasda (B) plus S, Lenvatinib, Lenvima, Sorafenib, Nexavar, Donafenib, Zepsun, Regorafenib, stivarga, apatinib plus camrelizumab, Apa plus C, Anti-PD-1 monoclonal antibody, PD-1 inhibitor | Wan-Guang Zhang, Chinese Cooperative Group of Liver Cancer (CCGLC), Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province, Haplox Biotechnology Co., Ltd., Geneplus-Beijing Co. Ltd., The Second Affiliated Hospital of Fujian Medical University | Hepatocellular Carcinoma Non-resectable | 04/24 | 12/24 | | |
| Li, Shiyong |
| Recruiting | 4 | 3400 | RoW | Sodium Bicarbonate Ringer's Injection, Sodium Lactated Ringer's Injection | Tongji Hospital | Acute Kidney Injury | 06/23 | 08/23 | | |
NCT04967872: Perioperative Management of Risk Factors in the Elderly Patients |
|
|
| Recruiting | N/A | 2650 | RoW | Implementing risk management and control plan for the elderly during perioperative period | Ailin Luo, Renmin Hospital of Wuhan University, Beijing Hospital, Chinese Academy of Medical Sciences, Fuwai Hospital | Perioperative Cardiavascular Complication, Peroperative Complication, Perioperative Pulmonary Complication, Perioperative Neurological Complication | 04/24 | 12/24 | | |
NCT05810363: The Safety of Etomidate - Propofol Mixture vs Propofol in Total Intravenous Anesthesia During Abdominal Surgery |
|
|
| Recruiting | N/A | 468 | RoW | Etomidate - propofol mixture, EP, Propofol, P | Ailin Luo | Etomidate, Hypotension | 05/24 | 08/24 | | |
| Ding, Ze-yang |
CCGLC-011, NCT06187961: Combined HAIC, Lenvatinib and Cadonilimab As Conversion Therapy for Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 36 | RoW | HAIC, hepatic arterial infusion chemotherapy of FOLFOX, Lenvatinib plus cadonilimab, levima plus cadonilimab | Tongji Hospital, Akesobio | Hepatocellular Carcinoma Non-resectable | 12/25 | 06/27 | | |
CCGLC-012, NCT06192784: Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 36 | RoW | DEB-TACE, drug eluting beads-transcatheter arterial chemoembolization, Lenvatinib plus pucotenlimab, levima plus pucotenlimab | Tongji Hospital, Geneplus-Beijing Co. Ltd., Chinese Cooperative Group of Liver Cancer (CCGLC) | Cholangiocarcinoma Non-resectable | 01/25 | 06/25 | | |
CCGLC-013, NCT06192797: Combined HAIC, Lenvatinib and Pucotenlimab As Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 36 | RoW | HAIC, hepatic arterial infusion chemotherapy of GEMOX, Lenvatinib plus pucotenlimab, levima plus pucotenlimab | Tongji Hospital, Geneplus-Beijing Co. Ltd., Chinese Cooperative Group of Liver Cancer | Cholangiocarcinoma Non-resectable | 12/26 | 06/28 | | |
CCGLC-007, NCT05533892: Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC |
|
|
| Recruiting | 1 | 30 | RoW | Nocardia rubra cell wall skeleton, N-CWS, Hepatic arterial infusion chemotherapy, HAIC, Lenvatinib, JieLiEn, Tislelizumab, BaiZeAn | Wan-Guang Zhang, Chinese Cooperative Group of Liver Cancer (CCGLC), Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province, M&R Pharm, Geneplus-Beijing Co. Ltd., Yuce Biotechnology Co., Ltd., Geneis, Simcere Pharmaceutical Co., Ltd, BeiGene, Haplox Biotechnology Co., Ltd. | Hepatocellular Carcinoma | 08/24 | 02/25 | | |
CCGLC-003, NCT05031949: Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma |
|
|
| Recruiting | 1 | 20 | RoW | hyperbaric oxygen therapy plus Camrelizumab | Zhang Bi Xiang, MD | Combinational Immunotherapy, Hepatocellular Carcinoma Non-Resectable, Hyperbaric Oxygen Therapy | 12/24 | 06/25 | | |
CCGLC-009, NCT06194695: DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | N/A | 100 | RoW | drug eluting beads-transcatheter arterial chemoembolization, DEB-TACE, envatinib plus anti-PD(L)1 | Ze-yang Ding, MD, Geneplus-Beijing Co. Ltd., Chinese Cooperative Group of Liver Cancer (CCGLC) | Cholangiocarcinoma Non-resectable | 12/24 | 06/25 | | |
| Recruiting | N/A | 300 | RoW | TACE, transarterial chemoembolization, Lenvatinib, levima, Anti-PD-1 monoclonal antibody, PD-1 inhibitor, Bevacizumab Biosimilar IBI305 plus sintilimab, Byvasda (B) plus S, Bevacizumab plus Atezolizumab, Avastin plus Tecentriq, apatinib plus camrelizumab, Apa plus C, Sorafenib, Nexavar, Donafenib, Zepsun, Regorafenib, stivarga | Tongji Hospital, Chinese Cooperative Group of Liver Cancer, Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province, The Second Affiliated Hospital of Fujian Medical University, Geneplus-Beijing Co. Ltd., Haplox Biotechnology Co., Ltd. | Hepatocellular Carcinoma Non-resectable | 12/23 | 12/24 | | |
CCGLC-001, NCT05713994: Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 300 | RoW | HAIC, hepatic arterial infusion chemotherapy of FOLFOX, Bevacizumab plus Atezolizumab, Avastin plus Tecentriq, Bevacizumab Biosimilar IBI305 plus sintilimab, Byvasda (B) plus S, Lenvatinib, Lenvima, Sorafenib, Nexavar, Donafenib, Zepsun, Regorafenib, stivarga, apatinib plus camrelizumab, Apa plus C, Anti-PD-1 monoclonal antibody, PD-1 inhibitor | Wan-Guang Zhang, Chinese Cooperative Group of Liver Cancer (CCGLC), Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province, Haplox Biotechnology Co., Ltd., Geneplus-Beijing Co. Ltd., The Second Affiliated Hospital of Fujian Medical University | Hepatocellular Carcinoma Non-resectable | 04/24 | 12/24 | | |
CCGLC-016, NCT06653127: Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Biliary Tract Cancer Recurrence Surveillance |
|
|
| Recruiting | N/A | 50 | RoW | Plasma and Tumor Tissue Mitochondrial DNA (mtDNA) Mutation Analysis | Tongji Hospital | Biliary Tract Cancer | 10/27 | 06/28 | | |
CCGLC-015, NCT06653062: Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveillance |
|
|
| Recruiting | N/A | 50 | RoW | Plasma and Tumor Tissue Mitochondrial DNA (mtDNA) Mutation Analysis | Tongji Hospital | Hepatocellular Carcinoma (HCC) | 12/27 | 06/28 | | |
| Recruiting | N/A | 2000 | RoW | | Tongji Hospital, Chinese Cooperative Group of Liver Cancer (CCGLC), Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province, Haplox Biotechnology Co., Ltd., Geneplus-Beijing Co. Ltd., YuceBio Technology, Gelesis, Inc. | Hepatocellular Carcinoma, Biliary Tract Neoplasms | 12/24 | 03/25 | | |
CCGLC-006, NCT05520788: Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing |
|
|
| Recruiting | N/A | 200 | RoW | precise medicine | Tongji Hospital | Hepatocellular Carcinoma, Biliary Tract Cancer | 12/25 | 12/25 | | |
| XIAOHUA, ZHU |
NCT05533086: PD-L1 PET Imaging in Patients With the Immunotherapy for Non-small Cell Lung Cancer |
|
|
| Recruiting | N/A | 20 | RoW | | Xiaohua Zhu | NSCLC Stage IV, PD-L1 Gene Amplification | 08/24 | 08/25 | | |
NCT05535621: 68Ga-HER2 Affibody PET/CT Imaging for HER2-Positive Cancer Patients |
|
|
| Recruiting | N/A | 100 | RoW | | Tongji Hospital | HER2-Positive Cancer | 12/24 | 12/25 | | |
NCT05541367: Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer |
|
|
| Recruiting | N/A | 80 | RoW | | Tongji Hospital | Breast Cancer, TNBC - Triple-Negative Breast Cancer, Estrogen-receptor-negative Breast Cancer | 12/26 | 12/26 | | |
| zhu, xiaohua |
NCT05538676: Fluoride-labeled Boronophenylalanine PET Imaging in Patients With Solid Tumors |
|
|
| Recruiting | N/A | 10 | RoW | BPA-PET imaging | Xiaohua Zhu | Solid Tumor, Adult | 08/23 | 08/25 | | |
NCT05533086: PD-L1 PET Imaging in Patients With the Immunotherapy for Non-small Cell Lung Cancer |
|
|
| Recruiting | N/A | 20 | RoW | | Xiaohua Zhu | NSCLC Stage IV, PD-L1 Gene Amplification | 08/24 | 08/25 | | |
NCT05535621: 68Ga-HER2 Affibody PET/CT Imaging for HER2-Positive Cancer Patients |
|
|
| Recruiting | N/A | 100 | RoW | | Tongji Hospital | HER2-Positive Cancer | 12/24 | 12/25 | | |
NCT05541367: Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer |
|
|
| Recruiting | N/A | 80 | RoW | | Tongji Hospital | Breast Cancer, TNBC - Triple-Negative Breast Cancer, Estrogen-receptor-negative Breast Cancer | 12/26 | 12/26 | | |
